Are TSLP, IL1RL1, and ORMDL3 variants linked to type 2 immune activation and asthma?

Genetic variations in epithelial-derived genes represent critical upstream determinants of airway inflammation and hyperreactivity, heavily influencing susceptibility to asthma and allergic diseases.

Clinical evidence and inflammation

• Specific risk alleles, such as the IL1RL1 rs1420101 (A allele) and the ORMDL3 rs7216389 (T allele), exhibit genome-wide significant associations with elevated peripheral blood eosinophil counts and fractional exhaled nitric oxide (FeNO).
• These variants represent some of the most robustly replicated genetic loci for childhood-onset asthma, atopy, and distinct eosinophilic, high-FeNO clinical phenotypes.

Mechanistic pathways

• TSLP activation: The TSLP promoter variant rs1837253 acts as a key regulatory variant that alters epithelial secretion of the TSLP alarmin, triggering downstream Type 2 helper T-cell cascades.
• IL-33/ST2 signaling: The IL1RL1 rs1420101 variant modulates the ST2 receptor, directly orchestrating IL-33-mediated Type 2 cytokine activation and downstream immune-cell recruitment.
• Sphingolipid regulation: At the 17q21 locus, the ORMDL3 rs7216389 risk allele increases ORMDL3 expression, which negatively regulates and inhibits serine palmitoyltransferase (SPT). This reduction in de novo sphingolipid and ceramide synthesis in the respiratory tract directly induces airway hyperreactivity (AHR), endoplasmic reticulum stress, skewed CD4+ T-cell differentiation, and epithelial barrier dysfunction.

Bottom line

• Genetic variants in TSLP, IL1RL1, and ORMDL3 are robust upstream drivers of epithelial immune activation and Type 2 immunity, directly linking molecular barrier dysfunction, ST2 receptor modulation, and sphingolipid pathway inhibition to eosinophilic asthma and allergic disease.